Anderson wins award for study of new drug designed to reduce oral side effects of cancer treatment

UI radiation oncologist Carryn Anderson, MD, has won the Steven M. Grunberg Memorial Award of the Multinational Association of Supportive Care in Cancer (MASCC) for her abstract examining early results from a phase 2b clinical trial of a drug designed to alleviate oral mucositis, a common and debilitating side effect of head and neck chemoradiation treatments.

Anderson led enrollment on a randomized, placebo-controlled trial testing placebo against a low dose versus a high dose of an investigational drug. The drug converts damaging particles created by radiation into particles that are more damaging to cancer cells and less damaging to normal tissue cells. The study was run by Galera Therapeutics and the University of Iowa and was offered at Holden Comprehensive Cancer Center and 44 other U.S. and Canadian cancer centers.

Anderson’s abstract received the highest score of all submissions for the 2018 MASCC annual meeting. As the winner of the award, Anderson will present the results of the trial and deliver the annual Steven Grunberg Lecture during the event, which takes place June 28–30 in Vienna, Austria.


  1. What a creative and clinically relevant approach! People like you improve the lives of countless patients.

  2. Congratulations Dr Anderson! I worked with you in OTO a little bit and all the patients just loved you. You are making a difference in many lives.

Comments are closed.